Combining Epitope-distinct Antibodies to HER2: Cooperative Inhibitory Effects on Invasive Growth

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2010 Dec 7

PMID 21132012

Citations 7

Authors

A Emde

C-R Pradeep

D A Ferraro

N Ben-Chetrit

M Sela

B Ribba

Z Kam

Y Yarden

Affiliations

Soon will be listed here.

Abstract

Monoclonal antibodies (mAbs) to HER2 are currently used to treat breast cancer, but low clinical efficacy, along with primary and acquired resistance to therapy, commonly limit clinical applications. We previously reported that combinations of antibodies directed at non-overlapping epitopes of HER2 are endowed with enhanced antitumor effects, probably due to accelerated receptor degradation. Here, we extend these observations to three-dimensional mammary cell models, and compare the effects of single mAbs with the effects of antibody combinations. Collectively, our in vitro assays and computational image analyses indicate that combining mAbs against different epitopes of HER2 better inhibits invasive growth. Importantly, while growth factors are able to reduce intraluminal apoptosis and induce an invasive phenotype, combinations of mAbs better than single mAbs can reverse the growth factor-induced phenotypes of HER2-overexpressing spheroids. In conclusion, our studies propose that mAb combinations negate the biological effects of growth factors on invasive growth of HER2-overexpressing cells. Hence, combining mAbs offers a therapeutic strategy, potentially able to enhance clinical efficacy of existing antireceptor immunotherapeutics.

Citing Articles

Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.

Parashar D, Nair B, Geethadevi A, George J, Nair A, Tsaih S Cancer Res. 2020; 80(24):5554-5568.

PMID: 33087324 PMC: 7744365. DOI: 10.1158/0008-5472.CAN-19-3717.

Targeting Cellular Trafficking of Fibroblast Growth Factor Receptors as a Strategy for Selective Cancer Treatment.

Porebska N, Latko M, Kucinska M, Zakrzewska M, Otlewski J, Opalinski L J Clin Med. 2018; 8(1).

PMID: 30577533 PMC: 6352210. DOI: 10.3390/jcm8010007.

Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.

Fattore L, Malpicci D, Marra E, Belleudi F, Noto A, De Vitis C Oncotarget. 2015; 6(28):24823-41.

PMID: 26208478 PMC: 4694796. DOI: 10.18632/oncotarget.4485.

Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.

Fauvel B, Yasri A MAbs. 2014; 6(4):838-51.

PMID: 24859229 PMC: 4171019. DOI: 10.4161/mabs.29089.

High-throughput epitope binning assays on label-free array-based biosensors can yield exquisite epitope discrimination that facilitates the selection of monoclonal antibodies with functional activity.

Abdiche Y, Miles A, Eckman J, Foletti D, Van Blarcom T, Yeung Y PLoS One. 2014; 9(3):e92451.

PMID: 24651868 PMC: 3961344. DOI: 10.1371/journal.pone.0092451.

References

Kasprzyk P, Song S, Di Fiore P, King C . Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res. 1992; 52(10):2771-6. View

Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller W, Inghirami G . Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell. 2006; 126(3):489-502. DOI: 10.1016/j.cell.2006.05.047. View

Seton-Rogers S, Brugge J . ErbB2 and TGF-beta: a cooperative role in mammary tumor progression?. Cell Cycle. 2004; 3(5):597-600. View

Nahta R, Esteva F . Herceptin: mechanisms of action and resistance. Cancer Lett. 2006; 232(2):123-38. DOI: 10.1016/j.canlet.2005.01.041. View

Hu M, Yao J, Carroll D, Weremowicz S, Chen H, Carrasco D . Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008; 13(5):394-406. PMC: 3705908. DOI: 10.1016/j.ccr.2008.03.007. View

Nahta R, Hung M, Esteva F . The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004; 64(7):2343-6. DOI: 10.1158/0008-5472.can-03-3856. View

Spangler J, Neil J, Abramovitch S, Yarden Y, White F, Lauffenburger D . Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A. 2010; 107(30):13252-7. PMC: 2922117. DOI: 10.1073/pnas.0913476107. View

Weiner D, Nordberg J, Robinson R, Nowell P, Gazdar A, Greene M . Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res. 1990; 50(2):421-5. View

Yip Y, Smith G, Koch J, Dubel S, Ward R . Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J Immunol. 2001; 166(8):5271-8. DOI: 10.4049/jimmunol.166.8.5271. View

10.

Zhan L, Xiang B, Muthuswamy S . Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors. Cancer Res. 2006; 66(10):5201-8. DOI: 10.1158/0008-5472.CAN-05-4081. View

11.

Lemieux J, Clemons M, Provencher L, Dent S, Latreille J, Mackey J . The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers. Curr Oncol. 2009; 16(5):48-57. PMC: 2768514. DOI: 10.3747/co.v16i5.510. View

12.

Hynes N, MacDonald G . ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009; 21(2):177-84. DOI: 10.1016/j.ceb.2008.12.010. View

13.

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

14.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

15.

Ben-Kasus T, Schechter B, Sela M, Yarden Y . Cancer therapeutic antibodies come of age: targeting minimal residual disease. Mol Oncol. 2009; 1(1):42-54. PMC: 5543854. DOI: 10.1016/j.molonc.2007.01.003. View

16.

Klapper L, Vaisman N, HURWITZ E, Pinkas-Kramarski R, Yarden Y, Sela M . A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene. 1997; 14(17):2099-109. DOI: 10.1038/sj.onc.1201029. View

17.

Spiridon C, Ghetie M, Uhr J, Marches R, Li J, Shen G . Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res. 2002; 8(6):1720-30. View

18.

Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M . Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A. 2009; 106(9):3294-9. PMC: 2651295. DOI: 10.1073/pnas.0812059106. View

19.

Ueda Y, Wang S, Dumont N, Yi J, Koh Y, Arteaga C . Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem. 2004; 279(23):24505-13. DOI: 10.1074/jbc.M400081200. View

20.

Friedman L, Rinon A, Schechter B, Lyass L, Lavi S, Bacus S . Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A. 2005; 102(6):1915-20. PMC: 548578. DOI: 10.1073/pnas.0409610102. View